OBJECTIVES: The aim of this study was to examine the relation of galectin-3 (Gal-3), a marker of cardiac fibrosis, with incident heart failure (HF) in the community. BACKGROUND: Gal-3 is an emerging prognostic biomarker in HF, and experimental studies suggest that Gal-3 is an important mediator of cardiac fibrosis. Whether elevated Gal-3 concentrations precede the development of HF is unknown. METHODS: Gal-3 concentrations were measured in 3,353 participants in the Framingham Offspring Cohort (mean age 59 years; 53% women). The relation of Gal-3 to incident HF was assessed using proportional hazards regression. RESULTS: Gal-3 was associated with increased left ventricular mass in age-adjusted and sex-adjusted analyses (p = 0.001); this association was attenuated in multivariate analyses (p = 0.06). A total of 166 participants developed incident HF and 468 died during a mean follow-up period of 11.2 years. Gal-3 was associated with risk for incident HF (hazard ratio [HR]: 1.28 per 1 SD increase in log Gal-3; 95% confidence interval [CI]: 1.14 to 1.43; p < 0.0001) and remained significant after adjustment for clinical variables and B-type natriuretic peptide (HR: 1.23; 95% CI: 1.04 to 1.47; p = 0.02). Gal-3 was also associated with risk for all-cause mortality (multivariable-adjusted HR: 1.15; 95% CI: 1.04 to 1.28; p = 0.01). The addition of Gal-3 to clinical factors resulted in negligible changes to the C-statistic and minor improvements in net reclassification improvement. CONCLUSIONS: Higher concentration of Gal-3, a marker of cardiac fibrosis, is associated with increased risk for incident HF and mortality. Future studies evaluating the role of Gal-3 in cardiac remodeling may provide further insights into the role of Gal-3 in the pathophysiology of HF.
OBJECTIVES: The aim of this study was to examine the relation of galectin-3 (Gal-3), a marker of cardiac fibrosis, with incident heart failure (HF) in the community. BACKGROUND:Gal-3 is an emerging prognostic biomarker in HF, and experimental studies suggest that Gal-3 is an important mediator of cardiac fibrosis. Whether elevated Gal-3 concentrations precede the development of HF is unknown. METHODS:Gal-3 concentrations were measured in 3,353 participants in the Framingham Offspring Cohort (mean age 59 years; 53% women). The relation of Gal-3 to incident HF was assessed using proportional hazards regression. RESULTS:Gal-3 was associated with increased left ventricular mass in age-adjusted and sex-adjusted analyses (p = 0.001); this association was attenuated in multivariate analyses (p = 0.06). A total of 166 participants developed incident HF and 468 died during a mean follow-up period of 11.2 years. Gal-3 was associated with risk for incident HF (hazard ratio [HR]: 1.28 per 1 SD increase in log Gal-3; 95% confidence interval [CI]: 1.14 to 1.43; p < 0.0001) and remained significant after adjustment for clinical variables and B-type natriuretic peptide (HR: 1.23; 95% CI: 1.04 to 1.47; p = 0.02). Gal-3 was also associated with risk for all-cause mortality (multivariable-adjusted HR: 1.15; 95% CI: 1.04 to 1.28; p = 0.01). The addition of Gal-3 to clinical factors resulted in negligible changes to the C-statistic and minor improvements in net reclassification improvement. CONCLUSIONS: Higher concentration of Gal-3, a marker of cardiac fibrosis, is associated with increased risk for incident HF and mortality. Future studies evaluating the role of Gal-3 in cardiac remodeling may provide further insights into the role of Gal-3 in the pathophysiology of HF.
Authors: G de Simone; S R Daniels; R B Devereux; R A Meyer; M J Roman; O de Divitiis; M H Alderman Journal: J Am Coll Cardiol Date: 1992-11-01 Impact factor: 24.094
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Torbjorn Omland; Philip A Wolf; Ramachandran S Vasan Journal: N Engl J Med Date: 2004-02-12 Impact factor: 91.245
Authors: Ramachandran S Vasan; Emelia J Benjamin; Martin G Larson; Eric P Leip; Thomas J Wang; Peter W F Wilson; Daniel Levy Journal: JAMA Date: 2002-09-11 Impact factor: 56.272
Authors: Anahita Ghorbani; Vijeta Bhambhani; Robert H Christenson; Wouter C Meijers; Rudolf A de Boer; Daniel Levy; Martin G Larson; Jennifer E Ho Journal: J Am Coll Cardiol Date: 2018-12-25 Impact factor: 24.094
Authors: Catherine E Simpson; Rachel L Damico; Paul M Hassoun; Lisa J Martin; Jun Yang; Melanie K Nies; R Dhananjay Vaidya; Stephanie Brandal; Michael W Pauciulo; Eric D Austin; D Dunbar Ivy; William C Nichols; Allen D Everett Journal: Chest Date: 2020-01-25 Impact factor: 9.410
Authors: Lori B Daniels; Paul Clopton; Gail A Laughlin; Alan S Maisel; Elizabeth Barrett-Connor Journal: Am Heart J Date: 2014-02-18 Impact factor: 4.749
Authors: Iftach Shaked; David B Hanna; Christian Gleißner; Brenda Marsh; Jill Plants; Daniel Tracy; Kathryn Anastos; Mardge Cohen; Elizabeth T Golub; Roksana Karim; Jason Lazar; Vinayaka Prasad; Phyllis C Tien; Mary A Young; Alan L Landay; Robert C Kaplan; Klaus Ley Journal: Arterioscler Thromb Vasc Biol Date: 2014-03-20 Impact factor: 8.311
Authors: Benjamin French; Le Wang; Bonnie Ky; Jeffrey Brandimarto; Anupam Basuray; James C Fang; Nancy K Sweitzer; Thomas P Cappola Journal: J Card Fail Date: 2015-11-10 Impact factor: 5.712